Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 12 · below the Ichimoku cloud · RSI 36 · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in 9939.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 9939.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 16, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.22 per share. | 145K | $31.68K |
| Jun 24, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.26 per share. | 250K | $65.75K |
| Jun 8, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.31 per share. | 75K | $23.31K |
| Jun 4, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.32 per share. | 125K | $40.17K |
| Jun 3, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.33 per share. | 50K | $16.59K |
| May 27, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.28 per share. | 190K | $54.07K |
| May 26, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.30 per share. | 42K | $12.49K |
| May 25, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.32 per share. | 110K | $34.74K |
| May 20, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.34 per share. | 38K | $12.80K |
| May 18, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.35 per share. | 70K | $24.48K |
| May 17, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.36 per share. | 170K | $60.77K |
| May 7, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.37 per share. | 80K | $29.53K |
| Apr 23, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.34 per share. | 28K | $9.42K |
| Apr 20, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.35 per share. | 48K | $16.66K |
| Apr 16, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.35 per share. | 10K | $3.51K |
| Apr 15, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.35 per share. | 290K | $102.66K |
| Apr 8, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.34 per share. | 50K | $16.85K |
| Apr 7, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.34 per share. | 65K | $22.41K |
| Apr 1, 2026 | Tong (Youzhi)Chief Executive Officer | Acquisition at price 0.33 per share. | 71.5K | $23.66K |
| Mar 30, 2026 | Tong (Youzhi)Chief Executive Officer | — | 1.25M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.9 | -5.0 | -7.1 | 14.1 | -19.0 | -17.0 | -11.0 | 0.6 | 2.9 | -9.9 | −19.1% | ||
| 2025 | -8.2 | 24.7 | 17.1 | -7.7 | 20.0 | 4.9 | 69.5 | -13.3 | 7.7 | -21.3 | 8.5 | -3.9 | +102.1% |
| 2024 | -25.8 | 8.3 | -34.4 | 8.1 | 30.1 | -14.0 | -1.9 | -10.8 | 28.6 | -6.8 | 0.0 | -11.0 | −40.5% |
| 2023 | 5.8 | -7.1 | -33.4 | -16.1 | -29.0 | -6.5 | 11.4 | -13.0 | -21.3 | -4.4 | -24.8 | -17.3 | −83.5% |
| 2022 | -36.4 | 62.1 | -23.1 | 132.8 | 5.5 | -21.9 | -19.3 | -2.9 | -24.0 | 11.7 | 6.9 | -25.9 | −19.9% |
| 2021 | 33.3 | 21.1 | 115.9 | 93.4 | -4.0 | -6.9 | 17.2 | 5.6 | -33.0 | -25.7 | 45.2 | -78.2 | +17.6% |
| 2020 | 4.4 | 2.7 | -8.5 | -35.4 | -15.3 | 8.3 | 24.8 | −27.5% |
No analyst coverage for this instrument.
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
No recent headlines.